StockData
TriSalus Life Sciences, Inc. logo

TriSalus Life Sciences, Inc. (TLSI) company profile

TLSINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as TLSIW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$2.45+0.16 (+6.75%)

Close on Nov 18, 2026Market cap $150.86MP/E –Yield –

About TriSalus Life Sciences

Surgical & Medical Instruments & Apparatus, SIC 3841

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that develops drug delivery systems and investigational therapeutics for treating solid tumors. Its primary commercial product is the TriNav Infusion System, which utilizes Pressure-Enabled Drug Delivery technology and SmartValve mechanisms to overcome high intratumoral pressure during interventional embolization procedures. The business operates across delivery device technology and investigational immunotherapy segments, including development of nelitolimod and the Pancreatic Retrograde Venous Infusion system. Its direct customers comprise hospital value analysis committees, interventional radiologists, medical oncologists, and related clinical support personnel.

The enterprise markets its proprietary devices across the United States through a dedicated commercial network of 43 sales and marketing professionals. Its delivery technology has been deployed in more than 31,000 clinical procedures across multiple participating hospitals, ambulatory surgery centers, and academic medical institutions. TriSalus Life Sciences is incorporated under the laws of Delaware, with the provided report text containing no specific details regarding its corporate headquarters.

Summary of the business section of TriSalus Life Sciences's latest annual report, written by StockData.

Company profile

Company

Legal name
TriSalus Life Sciences, Inc.
Headquarters
Westminster, CO
Address
6272 West 91st Avenue 80031
Phone
(415) 336-8917
Employees
102, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Grant Thornton LLP, Chicago, Illinois

Stock & identifiers

Ticker
TLSI
Other tickers
TLSIW
Former tickers
MTAC until Aug 16, 2023
Exchange
Nasdaq
IPO date
Dec 21, 2020
Shares outstanding
62M, Aug 4, 2026
Public float
$111.50M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1826667
CUSIP
89680M101
ISIN
US89680M1018
FIGI
BBG00Z1TKRG8
Share class FIGI
BBG00Z1TKRH7
EIN
85-3009869

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mary T. SzelaCEO and President, Director1,074,990
Richard MarshakChief Commercial Officer127,450
Jennifer StevensChief Regulatory Officer123,794
Bryan F. CoxChief of Research162,805
David PatienceChief Financial Officer261,107
Richard Henry MarshallChief Medical Officer30,000
Jodi DevlinChief of Clinical Operations97,364
James Emmett YoungChief Financial Officer79,663
Mats WahlstromDirector3,012,030
Gary B. GordonDirector72,510
Michael P. StanskyDirector1,640,420
William ValleDirector83,241
Kerry R. HicksDirector2,317,400
David J. MatlinDirector1,300,145
Sean MurphyDirector679,256
Arjun JJ DesaiDirector247,127
Liselotte HyveledDirector10,040

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.82M$6.89M$2.50M$83–
FY2024$4.14M$1.52M$1.85M$59–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Mary Szela
CEO and President
$600.92K$153.12K$2.57M$1.48M$15.80K$4.82M+17%
David Patience
Chief Financial Officer(*)
$268.46K$239.19K$1.14M$1.72M$77.68K$3.44M–
Richard Marshak
Chief Commercial Officer
$435.33K$113.54K$399.25K$592.28K$15.61K$1.56M+14%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Dec 21, 2020
Offer price
$10.00
Securities offered
3,300,000
Gross proceeds
$33.00M
Exchange
Nasdaq
First trading day
Feb 8, 2021
First-day close
$10.52+5.2%
Lock-up ends (est.)
Aug 7, 2021

“Each unit has an offering price of $10.00 and consists of one share of our Class A common stock and one-third of one redeemable warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 102 full-time employees,”

Corporate history

Events identified from SEC filings

DateEventDetails
Jun 23, 2025MergerRegistration of securities for a merger or exchange offer (S-4)
Mar 28, 2025Late filingNotification of late filing
May 24, 2024MergerRegistration of securities for a merger or exchange offer (S-4)
Apr 16, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 2, 2024Late filingNotification of late filing
Aug 16, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 16, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 10, 2023DelistingNotice of delisting from exchange (Form 25)
Aug 10, 2023Name changeName changed from MedTech Acquisition Corp to TriSalus Life Sciences, Inc.
Jun 21, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 6, 2023MergerRegistration of securities for a merger or exchange offer (S-4)
Feb 14, 2022Merger voteDefinitive merger proxy statement
Jun 2, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 17, 2021Late filingNotification of late filing
Dec 21, 2020IPOInitial public offering priced (424B4 prospectus)
Dec 16, 2020ListingRegistration of securities on an exchange (Form 8-A)
Oct 29, 2020Name changeName changed from MedTech Acquisition Corporation to MedTech Acquisition Corp

See a number that looks wrong?